Despite the complexity of the tumor microenvironment, which requires further confirmation including in vivo study, this work revealed a new approach of combining RN486 with conventional or innovative anticancer drugs for cancer patients diagnosed with overexpressed ABCB1 and ABCG2. Here, ABCG2 is linked to neoplasm.